Promising potential treatment for ovarian cancer reaches final stages of clinical trials

Dr Richard Penson and VBL Therapeutics are developing a new anti-ovarian cancer gene therapy treatment, VB-111

Ovarian cancer is one of the most dangerous forms of cancer. A treatment approach using platinum-based chemotherapy compounds is commonly used, however some tumour cells are resistant to the drugs used in this process. VBL Therapeutics is developing a promising new anti-cancer gene therapy: VB-111. With its unique dual mode of action, it targets the tumour environment by disrupting the […]

Read More…

Exciting advancements in ovarian cancer treatment

Exciting advancements in ovarian cancer treatment

Ovarian cancer is treacherous and challenging to treat. With standard treatment unchanged since the 1990s and newer costly treatments failing to restrain the tumour’s growth over long periods of time, an overhaul in anti-cancer treatment is urgently needed. With fresh insights into the biology and progression of ovarian cancer, Lev Ashraphyan, Vsevolod Kiselev from Institute of Gynecologic Oncology and Mammology […]

Read More…

Thank you for expressing interest in joining our mailing list and community. Below you can select how you’d like us to interact with you and we’ll keep you updated with our latest content.

You can change your preferences or unsubscribe by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at audience@researchoutreach.org at any time and if you have any questions about how we handle your data, please review our privacy agreement.

Would you like to learn more about our services?

We use MailChimp as our marketing automation platform. By clicking below to submit this form, you acknowledge that the information you provide will be transferred to MailChimp for processing in accordance with their Privacy Policy and Terms.

Subscribe to our FREE PUBLICATION